Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Seamus Fernandez maintains a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and raises the price target from $44 to $91.
March 05, 2024 | 5:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Seamus Fernandez maintains a Buy rating on Apogee Therapeutics and raises the price target from $44 to $91.
The significant increase in the price target by a reputable analyst like Seamus Fernandez from Guggenheim is likely to instill confidence among investors and could lead to a short-term increase in the stock price of Apogee Therapeutics. The doubling of the price target reflects a strong bullish outlook on the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100